Levosimendan Kalceks (Levosimendan)

Levosimendan enhances the sensitivity of cardiac troponin C to calcium, which increases the strength of heart muscle contraction without raising intracellular calcium levels. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and lowering afterload.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. It is typically administered as an intravenous infusion, starting with a loading dose followed by a maintenance infusion, but exact amounts are individualized.

Safety data for levosimendan in pregnancy and lactation are limited. It is generally avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss risks and alternatives with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Unlike catecholamine inotropes that increase intracellular calcium, levosimendan sensitises troponin C to existing calcium, reducing the risk of calcium‑mediated toxicity. It also provides vasodilation through potassium‑channel opening, offering a combined inotropic and afterload‑reducing effect that can be advantageous in certain heart‑failure patients.

Levosimendan Kalceks should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and potency.

Levosimendan is given intravenously, usually beginning with a loading infusion over 10 minutes followed by a continuous maintenance infusion for up to 24 hours. Administration is performed in a monitored clinical setting where blood pressure, heart rate, and cardiac output can be observed.

The most serious risks include severe hypotension, ventricular arrhythmias, and myocardial ischemia. Patients should be closely monitored for rapid drops in blood pressure, abnormal heart rhythms, and signs of chest pain, with immediate intervention available if these events occur.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, uncontrolled severe hypotension, or those receiving other potent vasodilators that could cause dangerous blood‑pressure drops. Caution is also advised in individuals with severe hepatic impairment or unstable arrhythmias.